Editas Medicine
EDIT on Nasdaq. Editas Medicine sells medicines that edit genes to patients with diseases. Market value $428m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-28.75 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 18 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$2.73 a share, 64% above its 1-year low
Over the past year the price has ranged from $1.66 to $4.54.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $26m | $20m | $78m | $32m | $41m |
| Operating margin | |||||
| Operating margin | -756.1% | -1146.3% | -216.6% | -777.2% | -394.9% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | 0.00 | 0.43 | 2.15 |
| Shares outstanding | |||||
| Shares outstanding | 0.07bn | 0.08bn | 0.08bn | 0.10bn | 0.15bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting checksSkipped: company is not yet profitable
- Debt2.15× equity
- Revenue growth, five yearsShrinking, 14.9% a year
- Buying back its own sharesNo, 123% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $12 million last quarter, up 232% on a year ago.
- A loss of $18 million, compared with a loss of $53 million a year ago.
- It loses 161 cents on each $1 of sales, compared with 617 cents a year earlier.
- 41% more shares than a year ago. Each share owns a bit less of the company.
- It has $126 million more cash than debt, up from $82 million a year ago.
- Sales grew on a year ago in 2 of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $61,000 |
| December 2024 | $31m |
| March 2025 | $5m |
| June 2025 | $4m |
| September 2025 | $8m |
| December 2025 | $25m |
| March 2026 | $3m |
| June 2026 | $12m |
| Quarter to | Amount |
|---|---|
| September 2024 | -$62m |
| December 2024 | -$45m |
| March 2025 | -$76m |
| June 2025 | -$53m |
| September 2025 | -$25m |
| December 2025 | -$6m |
| March 2026 | -$25m |
| June 2026 | -$18m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 9 March 2026
- Next quarterly (estimated, 10-Q)
- 4 November 2026
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 215 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Horizon KineticsMurray Stahl | $89,683 | <0.1% | Cut |
Largest holders overall
- TCG Crossover Management$36mNew
- BlackRock$34mAdded
- RA Capital Management, L.P.$29mNew
- Commodore Capital LP$29mNew
- ADAR1 Capital Management$29mNew
- Vanguard Capital Management$20mAdded
- Paradigm Biocapital Advisors LP$18mNew
- Opaleye Management$13mAdded
- Vanguard Portfolio Management$12mAdded
- Woodline Partners LP$12mNew
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
4 investors own more than 5%.
- TCG Crossover GP III, LLCPassive investorat least 9.9%(filed with 2 related holders)Since 27 May 2026
- Commodore Capital LPPassive investorat least 9.9%(filed with 3 related holders)Since 26 May 2026
- ADAR1 Capital Management, LLCPassive investorat least 5.8%(filed with 1 related holder)Since 30 June 2026
- RA Capital Management, L.P.Passive investorat least 5.8%(filed with 3 related holders)Since 27 May 2026
- BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2026
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
- Deep Track Capital, LPPassive investorSold down below 5%Since 31 December 2024
| Holder | Stake | Since | |
|---|---|---|---|
TCG Crossover GP III, LLC Passive investor | at least 9.9% (filed with 2 related holders) | 27 May 2026 | |
Commodore Capital LP Passive investor | at least 9.9% (filed with 3 related holders) | 26 May 2026 | |
ADAR1 Capital Management, LLC Passive investor | at least 5.8% (filed with 1 related holder) | 30 June 2026 | |
RA Capital Management, L.P. Passive investor | at least 5.8% (filed with 3 related holders) | 27 May 2026 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2026 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 | |
Deep Track Capital, LP Passive investor | Sold down below 5% | 31 December 2024 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 3 sold $106,688, $106,688 of it under preset trading plans.
- Parison AmySVP, Chief Financial OfficerSoldunder a preset trading plan
- Date
- 3 September 2026
- Shares
- 453
- Price
- $3.04
- Value
- $1,376
- Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERSoldunder a preset trading plan
- Date
- 3 September 2026
- Shares
- 709
- Price
- $3.04
- Value
- $2,153
- O'Neill Gilmore NeilCEO, DirectorSoldunder a preset trading plan
- Date
- 3 September 2026
- Shares
- 5,124
- Price
- $3.04
- Value
- $15,563
- Parison AmySVP, Chief Financial OfficerSoldunder a preset trading plan
- Date
- 3 August 2026
- Shares
- 678
- Price
- $2.58
- Value
- $1,749
- Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERSoldunder a preset trading plan
- Date
- 28 July 2026
- Shares
- 4,928
- Price
- $2.67
- Value
- $13,158
- Parison AmySVP, Chief Financial OfficerSoldunder a preset trading plan
- Date
- 3 June 2026
- Shares
- 464
- Price
- $2.70
- Value
- $1,253
- O'Neill Gilmore NeilCEO, DirectorSoldunder a preset trading plan
- Date
- 3 June 2026
- Shares
- 15,380
- Price
- $2.70
- Value
- $41,526
- Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERSoldunder a preset trading plan
- Date
- 3 June 2026
- Shares
- 731
- Price
- $2.70
- Value
- $1,974
- O'Neill Gilmore NeilCEO, DirectorSoldunder a preset trading plan
- Date
- 3 March 2026
- Shares
- 5,394
- Price
- $2.02
- Value
- $10,896
- Parison AmySVP, Chief Financial OfficerSoldunder a preset trading plan
- Date
- 3 March 2026
- Shares
- 474
- Price
- $2.02
- Value
- $957
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 3 September 2026 | Parison Amy SVP, Chief Financial Officer | Sold under a preset trading plan | 453 | $3.04 | $1,376 |
| 3 September 2026 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sold under a preset trading plan | 709 | $3.04 | $2,153 |
| 3 September 2026 | O'Neill Gilmore Neil CEO, Director | Sold under a preset trading plan | 5,124 | $3.04 | $15,563 |
| 3 August 2026 | Parison Amy SVP, Chief Financial Officer | Sold under a preset trading plan | 678 | $2.58 | $1,749 |
| 28 July 2026 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sold under a preset trading plan | 4,928 | $2.67 | $13,158 |
| 3 June 2026 | Parison Amy SVP, Chief Financial Officer | Sold under a preset trading plan | 464 | $2.70 | $1,253 |
| 3 June 2026 | O'Neill Gilmore Neil CEO, Director | Sold under a preset trading plan | 15,380 | $2.70 | $41,526 |
| 3 June 2026 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sold under a preset trading plan | 731 | $2.70 | $1,974 |
| 3 March 2026 | O'Neill Gilmore Neil CEO, Director | Sold under a preset trading plan | 5,394 | $2.02 | $10,896 |
| 3 March 2026 | Parison Amy SVP, Chief Financial Officer | Sold under a preset trading plan | 474 | $2.02 | $957 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the serious warning signs we check for were found. 1 thing worth knowing.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 9 Mar 2026, plus the 10-Q filed 5 Aug 2026 and 9 later 8-Ks.
Changed auditor
Worth knowingThe company changed its auditor (the firm that checks its books) in the last two years.
“On April 1, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors of Editas Medicine, Inc. (the “Company”) (i) dismissed Ernst & Young LLP (“Ernst & Young”) as the Company’s independent registered public accounting firm, effective immediately”
From an 8-K filed 7 April 2026: Change of auditor. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It carries a lot of debt: 2.1× its equity.
- Sales have shrunk: 14.9% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.